IsomAb makes two key appointments; Dr Shi Yin Foo M.D. as Non-Executive Director and Dr Gary Burgess M.D. as Chief Medical Officer

Aim to accelerate progress of lead candidate ISM-001 for peripheral ischaemia to clinic NOTTINGHAM, England, Feb. 25, 2025 /PRNewswire/ -- IsomAb Ltd, a UK-based biotechnology company developing novel isoform-specific disease modifying antibody treatments, for peripheral arterial disease...